{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:45:34Z","timestamp":1774917934357,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Prolonged dual antiplatelet therapy after 12 months in patients with previous myocardial infarction (MI) is attractive to reduce long-term ischemic complications. In the PEGASUS-TIMI 54, the use of low-dose ticagrelor (60 mg b.i.d.) plus aspirin after 12 months from MI reduced the risk of ischemic events, at the price of limited increase on bleeding complications. However, data on the use of low-dose ticagrelor in real-world practice lack. We aim at providing data on prescription\/eligibility criteria and outcomes in patients receiving low-dose ticagrelor in the real-world setting. We enrolled consecutive patients eligible for ticagrelor 60 mg according to Italian national regulation in 3 high-volume centers and collected 1-year outcomes. The primary objective of the study is to generate real-world data about clinical characteristics, eligibility criteria, major adverse cardiovascular events, bleeding, and adverse event in patients receiving low-dose ticagrelor from our cohort. One hundred eighty-one patients were consecutively enrolled with a median follow-up of 18 months. The most used and the least used prescription criteria were multivessel coronary disease (72.4%) and chronic kidney disease (15.5%), respectively. At 1-year follow-up, the rate of major adverse cardiovascular events was 4.97%; of these, 3.86% of patients had a MI, and 1.1% had a stroke\/transient ischemic attack, whereas no major bleeding occurred. In conclusion, in a real-world study, including patients with previous MI, low-dose ticagrelor for prolonged dual antiplatelet therapy showed to be effective and safe, with no major bleeding occurring at follow-up.<\/jats:p>","DOI":"10.1097\/fjc.0000000000000856","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T09:42:06Z","timestamp":1592818926000},"page":"173-180","source":"Crossref","is-referenced-by-count":40,"title":["Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study"],"prefix":"10.1097","volume":"76","author":[{"given":"Arturo","family":"Cesaro","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy;"},{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Taglialatela","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy;"},{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Moscarella","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy;"},{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Fimiani","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy;"},{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Conte","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy;"},{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Barletta","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy;"},{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Monda","sequence":"additional","affiliation":[{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"},{"name":"Division of Cardiology, Monaldi Hospital, Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"},{"name":"Division of Cardiology, Monaldi Hospital, Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Severino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Casa di cura \u201cS. Michele,\u201d Maddaloni (CE), Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli,\u201d Naples, Italy;"},{"name":"Division of Clinical Cardiology, A.O.R.N. \u201cSant'Anna e San Sebastiano,\u201d Caserta, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"NP1","DOI":"10.1177\/2047487316653709","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice the Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"23","author":"Piepoli","year":"2016","journal-title":"Eur J Prev Cardiol."},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y12 inhibitors","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation."},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med."},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J."},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-Term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med."},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet."},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/eurheartj\/ehm355","article-title":"Universal definition of myocardial infarction","volume":"28","author":"Thygesen","year":"2007","journal-title":"Eur Heart J."},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2018.08.055","article-title":"Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: the EYESHOT Post-MI study","volume":"273","author":"De Luca","year":"2018","journal-title":"Int J Cardiol."},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/clc.23262","article-title":"How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study","volume":"42","author":"De Luca","year":"2019","journal-title":"Clin Cardiol."},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2017.11.050","article-title":"Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease","volume":"71","author":"Bansilal","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N Engl J Med."},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"e007174","DOI":"10.1161\/JAHA.117.007174","article-title":"Culprit and nonculprit recurrent ischemic events in patients with myocardial infarction: data from SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-based care in Heart Disease Evaluated According to Recommended Therapies)","volume":"7","author":"Varenhorst","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"R13-20230915","first-page":"1","article-title":"Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction coronary artery disease","volume":"0","author":"lindholm","year":"2019","journal-title":"Heart."},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1161\/STROKEAHA.107.489807","article-title":"Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study","volume":"38","author":"Bos","year":"2007","journal-title":"Stroke."},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1055\/s-0038-1650576","article-title":"Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis","volume":"76","author":"Mezzano","year":"1996","journal-title":"Thromb Haemost."},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.amjcard.2018.05.049","article-title":"Impact of chronic renal failure on ischemic and bleeding events at 1 year in patients with acute coronary syndrome (from the multicenter START ANTIPLATELET registry)","volume":"122","author":"Patti","year":"2018","journal-title":"Am J Cardiol."},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjcvp\/pvv052","article-title":"Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting","volume":"2","author":"Guo","year":"2016","journal-title":"Eur Hear J Cardiovasc Pharmacother."},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS\u2013TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0186961","article-title":"Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome","volume":"12","author":"Patti","year":"2017","journal-title":"PLoS One."},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","article-title":"Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized dual antiplatelet therapy study","volume":"3","author":"Meredith","year":"2016","journal-title":"Circulation."},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/1570161117666190524123225","article-title":"Improving adherence to ticagrelor in patients after acute coronary syndrome: results from the PROGRESS trial","volume":"18","author":"Crisci","year":"2020","journal-title":"Curr Vasc Pharmacol."},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.amjcard.2019.08.030","article-title":"Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes (from the START-ANTIPLATELET registry)","volume":"124","author":"Calabr\u00f2","year":"2019","journal-title":"Am J Cardiol."},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J."},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T01:05:29Z","timestamp":1694739929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000856","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}